Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Published in
Journal for Immunotherapy of Cancer, December 2022
This research output has an Altmetric Attention Score of 318. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2025.
All research outputs
#135,181
of 34,601,305 outputs
Outputs from Journal for Immunotherapy of Cancer
#32
of 4,771 outputs
Outputs of similar age
#3,152
of 536,365 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#3
of 121 outputs
Altmetric has tracked 34,601,305 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,771 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 536,365 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 121 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.
